Immune Financial Statements From 2010 to 2021

IMUN -  USA Stock  

USD 1.71  0.04  2.29%

Immune Therapeutics financial statements provide useful quarterly and yearly information to potential Immune Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immune Therapeutics financial statements helps investors assess Immune Therapeutics' valuation, profitability, and current liquidity needs.
Immune Therapeutics does not presently have any fundamental trends for analysis.
.

Immune Financial Statements 

 
Refresh
Check Immune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immune main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Immune financial statements analysis is a perfect complement when working with Immune Therapeutics Valuation or Volatility modules. It can also supplement various Immune Therapeutics Technical models. Please see the analysis of Immune Therapeutics Correlation against competitors.

Immune Book Value Per Share Analysis

Immune Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Book Value per Share 
 = 
Common Equity 
Average Shares 
More About Book Value Per Share | All Equity Analysis

Current Immune Therapeutics Book Value Per Share

    
  (22.30) X  
Most of Immune Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Compare to competition

In accordance with the recently published financial statements, the book value per share of Immune Therapeutics is about -22.3 times. This is much higher than that of the Healthcare sector and 91.03% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 101.15% higher than that of the company.

Immune Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immune Therapeutics's current stock value. Our valuation model uses many indicators to compare Immune Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immune Therapeutics competition to find correlations between indicators driving Immune Therapeutics's intrinsic value. More Info.
Immune Therapeutics is rated fifth overall in total debt category among related companies. It is rated second overall in earnings per share category among related companies . The ratio of Total Debt to Earnings Per Share for Immune Therapeutics is about  466,424 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immune Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immune Therapeutics' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immune Therapeutics' earnings, one of the primary drivers of an investment's value.

About Immune Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immune Therapeutics income statement, its balance sheet, and the statement of cash flows. Immune Therapeutics investors use historical funamental indicators, such as Immune Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immune Therapeutics investors may use each financial statement separately, they are all related. The changes in Immune Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immune Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immune Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immune Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Immune Therapeutics Investors Sentiment

The influence of Immune Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Therapeutics' short interest history, or implied volatility extrapolated from Immune Therapeutics options trading.

Current Sentiment - IMUN

Immune Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on Immune Therapeutics. What is your judgment towards investing in Immune Therapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immune Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immune Therapeutics Correlation against competitors. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Is Immune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immune Therapeutics. If investors know Immune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.